This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

5 Stocks Insiders Love Right Now

Cyclacel Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A biotechnology stock that insiders are snapping up shares in here is Cyclacel Pharmaceuticals ( CYCC), which is engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Insiders are buying this stock into extreme weakness, since shares are down by 44% so far in 2013.

Cyclacel Pharmaceuticals has a market cap of $36 million and an enterprise value $21 million. This stock trades at a premium valuation, with a price-to-sales of 125.85 and a price-to-book of 3.46. This is a cash-rich company, since the total cash position on its balance sheet is $14.14 million and its total debt is zero.

The president just bought 100,000 shares, or $300,000 worth of stock, at $3.00 per share. The president also just bought another 100,000 shares, or $300,000 worth of stock, at $3.00 per share.

From a technical perspective, CYCC is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last three months, with shares dropping from its high of $6.05 to its recent low of $2.91 a share. During that downtrend, shares of CYCC have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of CYCC have started to bounce off that $2.91 low and off of oversold levels, since its relative strength index recently dipped well under 30.

If you're bullish on CYCC, then look for long-biased trades as long as this stock is trending above $3.20 or above $3 and then once it breaks out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 219,831 shares. If that breakout triggers soon, then CYCC will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day of $4.58 a share or its 200-day at $5.10 a share.

5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CYCC $0.90 -0.78%
EOX $0.71 -7.40%
MO $50.35 -0.36%
SREV $3.06 -2.90%
SWI $51.22 0.08%


DOW 17,886.73 -89.58 -0.50%
S&P 500 2,078.14 -8.10 -0.39%
NASDAQ 4,925.0860 -22.3550 -0.45%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs